Publish in this journal
Journal Information
Vol. 217. Issue 6.
Pages 365-369 (August - September 2017)
Share
Share
Download PDF
More article options
ePub
Visits
...
Vol. 217. Issue 6.
Pages 365-369 (August - September 2017)
For and Against
Anticoagulant therapy duration. In favor of short-term courses
Duración del tratamiento anticoagulante. A favor de plazos cortos
Visits
...
J.A. Nieto Rodríguez
Corresponding author
joseanietor@gmail.com

Corresponding author.
, J.C. Ramírez Luna
Servicio de Medicina Interna, Hospital Virgen de la Luz, Cuenca, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. A. Incidence of recurrent episodes of venous thromboembolism, recurrent symptomatic pulmonary embolism and fatal pulmonary embolism following the completion of anticoagulant therapy maintained for 3–6 months. B. Incidence of severe and fatal hemorrhage in patients with VTE and prolonged anticoagulation.
Abstract

In recent years, we have observed a tendency to extend anticoagulant therapy for patients with venous thromboembolism disease (VTE). This practice exposes patients to a greater risk of severe and fatal hemorrhage, which, in certain conditions, outweighs the benefits related to the reduction in disease recurrence. This review examines the evidence in favor of reducing anticoagulant therapy as much as possible, especially for patients with VTE “caused” by temporary risk factors, with isolated deep vein thrombosis and with unprovoked VTE and a high risk of hemorrhage.

Keywords:
Venous thromboembolism
Treatment duration
Anticoagulation
Relapses
Hemorrhages
Resumen

Durante los últimos años se ha observado una tendencia a prolongar la duración del tratamiento anticoagulante en los pacientes con enfermedad tromboembólica venosa (ETEV). Esto expone a los pacientes a un mayor riesgo de hemorragias graves y mortales que, en determinadas situaciones, superan los beneficios relacionados con la reducción de recurrencias de la enfermedad. En esta revisión se repasan las evidencias a favor de reducir al mínimo el tratamiento anticoagulante, especialmente en los pacientes con ETEV «provocada» por factores de riesgo transitorios, con trombosis venosa profunda aislada, y con ETEV «no provocada» y riesgo alto de hemorragia.

Palabras clave:
Tromboembolia venosa
Duración del tratamiento
Anticoagulación
Recurrencias
Hemorragias

Article

These are the options to access the full texts of the publication Revista Clínica Española (English Edition)
Member
Si es usted socio de FESEMI siga los siguientes pasos:

Diríjase desde aquí a la web de la >>>FESEMI<<< e inicie sesión mediante el formulario que se encuentra en la barra superior, pulsando sobre el candado.

Una vez autentificado, en la misma web de FESEMI, en el menú superior, elija la opción deseada.

>>>FESEMI<<<

Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Clínica Española (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Revista Clínica Española (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?